Autoimmune antibodies for use in inhibiting cancer cell growth

Abstract

The present disclosure provides, among other things, compositions (e.g., autoantibodies) that inhibit the growth, viability, or mobility of (invasion by) a cancer cell. Also provided are applications, such as therapeutic and diagnostic methods, in which the agents are useful, as well as screening methods for identifying autoantibodies useful in the applications.

1 . A method for inhibiting a cancer cell, the method comprising contacting the cancer cell with an autoimmune antibody obtained from one or more subjects suffering from an autoimmune disease, in an amount effective to inhibit the cancer cell. 
     
     
         2 . The method of  claim 1 , wherein the autoimmune antibody inhibits the growth of the cancer cell. 
     
     
         3 . The method of  claim 1 , wherein the autoimmune antibody inhibits the viability of the cancer cell. 
     
     
         4 . The method of  claim 1 , wherein the autoimmune antibody inhibits the mobility of the cancer cell. 
     
     
         5 . The method of  claim 1 , wherein the contacting occurs in vitro. 
     
     
         6 . The method of  claim 1 , wherein the contacting occurs in vivo. 
     
     
         7 . The method of  claim 1 , wherein the cancer cell is a lung cancer cell, breast cancer cell, colon cancer cell, pancreatic cancer cell, renal cancer cell, stomach cancer cell, liver cancer cell, bone cancer cell, hematological cancer cell, neural tissue cancer cell, melanoma, thyroid cancer cell, ovarian cancer cell, testicular cancer cell, prostate cancer cell, cervical cancer cell, vaginal cancer cell, or bladder cancer cell. 
     
     
         8 . The method of  claim 1 , wherein the cancer cell is contacted with more than one autoimmune antibody. 
     
     
         9 . The method of  claim 1 , wherein the cancer cell is contacted with blood or a blood fraction comprising one or more autoimmune antibodies. 
     
     
         10 . The method of  claim 9 , wherein the blood or blood fraction was obtained from a subject afflicted with lupus. 
     
     
         11 . The method of  claim 9 , wherein the blood or blood fraction was obtained from a subject afflicted with a dermatomyositis, scleroderma, rheumatoid arthritis, or multiple sclerosis. 
     
     
         12 . The method of  claim 1 , wherein the autoimmune antibody is a monoclonal antibody. 
     
     
         13 . A method for treating a subject afflicted with a cancer, the method comprising administering to the subject an autoimmune antibody obtained from one or more subjects suffering from an autoimmune disease, in an amount effective to treat the cancer. 
     
     
         14 . The method of  claim 13 , wherein the subject is a human. 
     
     
         15 . The method of  claim 14 , wherein the cancer is a lung cancer, breast cancer, colon cancer, pancreatic cancer, renal cancer, stomach cancer, liver cancer, bone cancer, hematological cancer, neural tissue cancer, melanoma, thyroid cancer, ovarian cancer, testicular cancer, prostate cancer, cervical cancer, vaginal cancer, or bladder cancer. 
     
     
         16 . The method of  claim 15 , wherein more than one autoimmune antibody is administered to the subject. 
     
     
         17 . The method of  claim 13 , wherein a blood or a blood fraction comprising one or more autoimmune antibodies is administered to the subject. 
     
     
         18 . The method of  claim 17 , wherein the blood or blood fraction was obtained from a subject afflicted with lupus. 
     
     
         19 . The method of  claim 17 , wherein the blood or blood fraction was obtained from a subject afflicted with a dermatomyositis, scleroderma, rheumatoid arthritis, or multiple sclerosis. 
     
     
         20 . The method of  claim 13 , wherein the autoimmune antibody is a monoclonal antibody. 
     
     
         21 . A method for identifying an antibody that inhibits a cancer cell, the method comprising:
 assaying in vitro the growth, viability, or mobility of a cancer cell in the presence of an antibody from a B cell obtained from a subject afflicted with an autoimmune disease, wherein a reduction in the growth, viability, or mobility of the cancer cell in the presence of the antibody, as compared to the growth, viability or mobility of the cancer cell in the absence of the antibody, identifies the antibody as an inhibitor of the cancer cell.   
     
     
         22 . The method of  claim 21 , wherein the assaying step is run in the absence of a stromal cell population. 
     
     
         23 . The method of  claim 21 , wherein the assaying step is run in the presence of a stromal cell population. 
     
     
         24 . The method of  claim 23 , wherein the stromal cell population is selected from the group consisting of fibroblasts, T-cells, B-cells, dendritic cells, and eosinophils. 
     
     
         25 . The method of  claim 21 , wherein the cancer cell is a group of cancer cells. 
     
     
         26 . A screening method for identifying one or more antibodies that inhibit a cancer cell, the method comprising:
 assaying in vitro the growth, viability, or mobility of a cancer cell in the presence of each antibody of a plurality of antibodies from a subject afflicted with an autoimmune disease, wherein a reduction in the growth, viability, or mobility of the cancer cell in the presence of at least one of the antibodies, as compared to the growth, viability or mobility of the cancer cell in the absence of the antibody, identifies the antibody as an inhibitor of the cancer cell.   
     
     
         27 . The method of  claim 26 , wherein the assaying step is run in the absence of a stromal cell population. 
     
     
         28 . The method of  claim 26 , wherein the assaying step is run in the presence of a stromal cell population. 
     
     
         29 . The method of  claim 28 , wherein the stromal cell population is selected from the group consisting of fibroblasts, T-cells, B-cells, dendritic cells, and eosinophils. 
     
     
         30 . The method of  claim 26 , wherein the cancer cell is a group of cancer cells. 
     
     
         31 . An antibody identified using the method of  claim 21 . 
     
     
         32 .- 44 . (canceled)